Protara Therapeutics (TARA): Is +890% Upside to $25 Within Reach?

Key Takeaways

• The central $25 target is the arithmetic mean of the verified analyst price targets reviewed for TARA, rounded from a calculated average near $25.33.
• At a recent price near $2.52, reaching $25 would require an upside of roughly 890%—an exceptionally large move for a pre-revenue biotech.
• Individual analyst targets span a wide range from about $18 to $30, reflecting genuine disagreement over TARA-002's commercial potential.
• The strongest support comes from positive TARA-002 efficacy data and multiple upcoming data readouts, including interim THRIVE-3 results expected in the fourth quarter of 2026.
• The biggest risks are binary clinical outcomes, no product revenue, and continued cash burn that makes the valuation highly dependent on trial success.
• For more context, explore Major News, Today's Price Move, the Forecast, and Earnings pages for Protara Therapeutics.

What Analysts Are Saying About TARA

The $25 central target reflects roughly eight current analyst price targets, spanning a broad range from about $18 to $30. The arithmetic mean of these figures lands near $25.33, which rounds to a clean $25 objective. The wide dispersion is itself informative: bullish firms such as TD Cowen and Oppenheimer have carried targets as high as $28 to $30, while more cautious houses such as LifeSci Capital have trimmed targets toward $20 as the shares declined. In between sit Piper Sandler, H.C. Wainwright, and JonesTrading with Buy ratings in the $24 to $27 range, and J.P. Morgan and Cantor Fitzgerald maintain positive ratings without publicly current price targets.

The consensus leans strongly bullish—rated Strong Buy or Buy by essentially all covering analysts—but the range signals genuine uncertainty about how quickly and how completely TARA-002 can reach the market. Analysts cite the strong complete-response data in BCG-unresponsive NMIBC, the potential for a rolling BLA submission in lymphatic malformations, and the company's manufacturing internalization as key drivers. No target here should be read as a guarantee; these are estimates, not forecasts of certainty. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Where TARA Stands Today and the Road Ahead

With shares near $2.52 and a 52-week range of roughly $2.09 to $7.82, TARA trades far below its prior highs after a pronounced multi-month decline. Moving to $25 would require a gain of approximately 890%, which qualifies as a very large move by any standard. For context, the stock has already fallen more than 50% over the trailing year, leaving the analyst targets—many set when shares traded materially higher—well above the current price.

The path toward such a level would almost certainly need to run through clinical and regulatory milestones rather than gradual fundamental improvement, since the company generates no product revenue. Confirmation of TARA-002's efficacy in registrational cohorts, a completed rolling BLA submission, and eventual regulatory approval would be the kind of catalysts that have historically re-rated clinical-stage biotech names dramatically.

Key Catalysts That Could Drive TARA Higher

The core thesis rests on TARA-002. In February 2026 the company reported a 68% complete-response rate at six months in BCG-unresponsive NMIBC patients, a difficult-to-treat population, with no grade 3 or higher treatment-related adverse events. Management expects to complete enrollment of the BCG-unresponsive registrational cohort of the ADVANCED-2 trial by year-end 2026 and to complete STARBORN-1 enrollment in early 2027, setting up a rolling BLA submission in lymphatic malformations. A roughly $8.75 million acquisition of Novex Innovations' TARA-002 manufacturing assets also internalizes production capacity ahead of a potential launch. The balance sheet provides runway: about $143 million in cash and equivalents as of September 30, 2026, projected to fund operations into 2028.

Risks That Could Hold TARA Back

The principal obstacle is binary clinical and regulatory risk. TARA-002's registrational data are not yet final, and later-stage results can underperform earlier readouts. The company is pre-revenue, with R&D expenses rising as trials advance—third-quarter 2026 R&D spending grew to about $16.8 million from roughly $9.6 million a year earlier—and net losses widening. Any delay, redesign, or disappointing efficacy or safety signal could compress the valuation sharply, especially given a limited pipeline concentrated around a single product approach. Macroeconomic pressure on speculative, cash-burning biotech names also tends to weigh on sentiment regardless of company-specific progress.

Looking at the Technical Picture

The stock's long-term structure reflects a deep drawdown from the $7.82 52-week high to the $2.09 low, with the current price sitting near the lower portion of that range. The prior high near $7.82 stands as a distant resistance zone, while the $2.09 low and the $2.50 area represent nearby support. Because the analyst targets sit far above any recent trading level, the stock would need to reclaim multiple psychological and prior-resistance zones—well before approaching $25—before the technical picture could confirm a sustained trend change.

What to Watch in the Coming Months

Analyst price targets generally reflect a research horizon of about 12 months, though individual firms may differ. The most consequential upcoming items are the interim results from the Phase 2b cohort of the THRIVE-3 trial of IV choline chloride, expected in the fourth quarter of 2026; completion of ADVANCED-2 enrollment by year-end; STARBORN-1 enrollment in early 2027; and progress toward a rolling BLA submission. Investors should also track cash burn, any additional financing, analyst target revisions, and updates on the redesigned ADVANCED-3 exploratory trial.

My Take: Can TARA Reach $25?

Can Protara Therapeutics (TARA) reach $25? The target is not a guarantee but the arithmetic mean of current analyst price targets spanning roughly $18 to $30. Reaching it would demand an increase of about 890% from a price near $2.52—an exceptionally large move justified only if TARA-002 delivers on its registrational promise and reaches the market. The bulls point to encouraging efficacy data, a cash runway into 2028, and a slate of near-term readouts; the bears emphasize pre-revenue status, widening losses, and binary clinical risk. The next meaningful signposts—THRIVE-3 interim data, trial enrollment completions, and BLA progress—will determine whether the gap between the current price and the $25 objective narrows or widens.

Exploring AI Daily Buy/Sell Signals

In my own research, I’ve found Tickeron’s AI Daily Buy/Sell Signals helpful for tracking momentum in names like TARA. The tool applies artificial intelligence to monitor market conditions and technical behavior across thousands of stocks, generating Buy, Sell, or Hold signals that can complement fundamental analysis. For clinical-stage biotechs that can shift quickly on data, this kind of systematic layer helps cut through noise and flag potential trend changes without replacing deeper due diligence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume